Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Eledon Pharmaceuticals (ELDN) Consolidated Net Income (2016 - 2026)

Eledon Pharmaceuticals filings provide 5 years of Consolidated Net Income readings, the most recent being -$2.1 million for Q4 2017.

  • On a quarterly basis, Consolidated Net Income rose 43.67% to -$2.1 million in Q4 2017 year-over-year; TTM through Dec 2017 was -$13.1 million, a 25.7% increase, with the full-year FY2025 number at -$45.6 million, down 26.07% from a year prior.
  • Consolidated Net Income hit -$2.1 million in Q4 2017 for Eledon Pharmaceuticals, up from -$3.0 million in the prior quarter.
  • In the past five years, Consolidated Net Income ranged from a high of -$883000.0 in Q2 2016 to a low of -$13.3 million in Q1 2015.
  • Median Consolidated Net Income over the past 5 years was -$5.7 million (2013), compared with a mean of -$6.0 million.
  • Biggest five-year swings in Consolidated Net Income: soared 90.14% in 2016 and later crashed 654.93% in 2017.
  • Eledon Pharmaceuticals' Consolidated Net Income stood at -$5.5 million in 2013, then dropped by 11.88% to -$6.2 million in 2014, then tumbled by 77.46% to -$11.0 million in 2015, then skyrocketed by 66.08% to -$3.7 million in 2016, then skyrocketed by 43.67% to -$2.1 million in 2017.
  • The last three reported values for Consolidated Net Income were -$2.1 million (Q4 2017), -$3.0 million (Q3 2017), and -$6.7 million (Q2 2017) per Business Quant data.